Quiet ASX debut for BioPharmica
Monday, 09 August, 2004
BioPharmica (ASX: BPH) made its debut on the ASX on Friday afternoon, closing slightly lower than its opening price of AUD$0.25 at $0.21.
The Perth-based company's IPO closed oversubscribed after raising $2.6 million at $0.20 per share in a spin-out from investment company Grandbridge (ASX: GBA), which stands to turn a $1 million profit from the listing.
BioPharmica is developing diagnostic and therapeutic applications for a tumour suppressor gene, HLS5, with a potential role in breast, prostate and colorectal cancers, based on research conducted at the Western Australian Institute of Medical Research.
A second project involves development of genetics-based diagnostic systems for bacterial infections, with an initial focus on diagnosing respiratory tract infections in partnerships with RMIT spin-off, Diagnostic Array Systems.
The company also announced the appointment of US-based consultant Richard O'Connor to its advisory board. Managing Director David Breeze said O'Connor's corporate experience and access to US networks was of the highest calibre.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
